Stat5 transcription factors, principal mediators of PRL effects [12,13], are frequently inactivated during metastatic progression in clinical breast cancer specimens, and loss of Stat5 signaling is associated with unfavorable prognosis and increased risk of anti-estrogen therapy failure [14-17]. Here, PRL is linked to breast carcinoma.